1 year ago
Aurobindo Pharma to Acquire Lannett, Gain US Manufacturing Base
Aurobindo Pharma, an Indian drug maker, is buying Lannett Company, a US-based company that makes generic medicines.
The deal is worth $250 million.
Lannett has a manufacturing plant in the US.
This deal helps Aurobindo produce medicines in the US, potentially avoiding any extra costs from tariffs on imported drugs.
This also gives Aurobindo access to government contracts and expands their product range.
Aurobindo Pharma USA Inc. will acquire Lannett Company LLC.
The deal is valued at $250 million.
Lannett is a US-based manufacturer of generic pharmaceuticals.
The acquisition provides Aurobindo with a US manufacturing base.
The deal may offset potential impacts of US tariffs.
- Who
- Aurobindo Pharma USA Inc. is acquiring Lannett Company LLC from Lannett Seller Holdco, Inc.
- What
- Aurobindo Pharma USA Inc. is acquiring Lannett Company LLC.
- Where
- Lannett is based in the USA, with a manufacturing facility.
- When
- The acquisition was announced on Wednesday, July 30, 2025.
- Why
- Aurobindo aims to expand its US manufacturing and offset potential tariff impacts.
Importers
Local Manufacturers
Tariff Concerns
Importers
Facing adverse impacts from tariffs on imports from India
Local Manufacturers
Benefiting from a US manufacturing base through local production, allowing Aurobindo to offset potential costs.
Key facts
- Acquirer
- Aurobindo Pharma USA Inc.
- Target
- Lannett Company LLC
- Deal Value
- $250 million (₹2,185 crore)
- Lannett Location
- Trevose, PA, USA
- Employees
- Over 430
- Facility Utilisation
- 40%
